- Trials with a EudraCT protocol (461)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (6)
461 result(s) found for: Predictive value.
Displaying page 1 of 24.
EudraCT Number: 2013-004671-12 | Sponsor Protocol Number: s55892 | Start Date*: 2014-06-20 |
Sponsor Name:University of Leuven | ||
Full Title: Predictive value of biomarkers in patients with amnestic mild cognitive impairment | ||
Medical condition: Mild cognitive impairment | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2009-011445-13 | Sponsor Protocol Number: IJB-BGDO-2009-001 | Start Date*: 2009-11-26 |
Sponsor Name:Institut Jules Bordet-Université Libre de Bruxelles | ||
Full Title: Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer | ||
Medical condition: Stage III colon adenocarcinoma | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-002217-22 | Sponsor Protocol Number: SJ-546 | Start Date*: 2016-09-02 | ||||||||||||||||
Sponsor Name:Sjællands University Hospital, Køge | ||||||||||||||||||
Full Title: Validation of stimulated ∆FGF19 for diagnosing bile acid diarrhoea | ||||||||||||||||||
Medical condition: Bile acid malabsorption / bile acid diarrhoea | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-001711-85 | Sponsor Protocol Number: PTF202 | Start Date*: 2022-03-10 | |||||||||||
Sponsor Name:PentixaPharm GmbH | |||||||||||||
Full Title: A prospective, international, multi-centre, open-label,single-arm phase II study investigating the predictive value of [68Ga]Ga-PentixaFor PET imaging in primary and isolated secondary CNS lymphom... | |||||||||||||
Medical condition: Central nervous system (CNS) lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) DK (Prematurely Ended) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000597-29 | Sponsor Protocol Number: 2017-02-CHRMT | Start Date*: 2021-06-02 |
Sponsor Name:Centre Hospitalier Régional Metz-Thionville | ||
Full Title: Interest of Nasal Provocation Tests for Diagnosis of House Mites Allergic Rhinitis | ||
Medical condition: mite allergenic rhinitis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-004174-34 | Sponsor Protocol Number: Citalopram2017 | Start Date*: 2018-04-10 |
Sponsor Name:Targid, KU Leuven | ||
Full Title: A placebo-controlled trial with citalopram for the treatment of typical reflux symptoms in patients with reflux hypersensitivity or functional heartburn with incomplete proton pump inhibitor response | ||
Medical condition: Functional heartburn and reflux hypersensitivity with incomplete respons to proton pomp inhibitors | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2004-003906-81 | Sponsor Protocol Number: A7-2 | Start Date*: 2005-01-14 |
Sponsor Name:Oncology Institute of Vilnius University | ||
Full Title: Chemoradiation with once weekly gemcitabine for invasive bladder cancer | ||
Medical condition: Invasive transitional cell bladder cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: LT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2006-001014-32 | Sponsor Protocol Number: 2006-001014-32 | Start Date*: 2006-07-28 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA POLICLINICO DI MODENA | |||||||||||||
Full Title: PHASE II STUDY OF BAY 43-9006 IN PATIENTS WITH ADVANCED CHOLANGIOCELLULAR CARCINOMA | |||||||||||||
Medical condition: ᄋ Patients should have proven primary CCC according to one of the following criteria: o Histological evidence of CCC on a biopsy specimen. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002624-16 | Sponsor Protocol Number: P170907J | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:ASSISTANC-PUBLIQUE-HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: Validation of respiratory epithelial functional assessment to predict clinical efficacy of Orkambi®. Pathway to personalized therapy in Cystic Fibrosis PREDICT-CF | |||||||||||||
Medical condition: Homozygous F508del patient aged 12 years or older | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000993-27 | Sponsor Protocol Number: 2019PI115 | Start Date*: 2020-07-16 | |||||||||||
Sponsor Name:CHRU NANCY | |||||||||||||
Full Title: AGATA: Value of contrast-enhanced ultrasound in adnexal torsion | |||||||||||||
Medical condition: Adnexal torsion | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002276-27 | Sponsor Protocol Number: PVSD-ICS | Start Date*: 2016-08-04 | |||||||||||
Sponsor Name:Medisch Spectrum Twente | |||||||||||||
Full Title: The predictive value of the acute effect of beclomethasone-dipropionate on a mannitol challenge test for the outcome of longterm treatment with beclomethasone-dipropionate in childhood asthma | |||||||||||||
Medical condition: exercise induced bronchoconstriction asthma | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004914-32 | Sponsor Protocol Number: NL71558.041.19 | Start Date*: 2020-03-12 | |||||||||||||||||||||
Sponsor Name:University Medical Center Utrecht | |||||||||||||||||||||||
Full Title: Sentinel lymph node (SLN) detection in early oral cancer using Gallium-68-Tilmanocept PET-CT | |||||||||||||||||||||||
Medical condition: The IMP will be used for the identification of sentinel lymph nodes in patients with early-stage oral squamous cell carcinoma and a clinically negative neck (T1-3N0M0). | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: NL (Temporarily Halted) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001885-14 | Sponsor Protocol Number: LOWBACK-SE | Start Date*: 2019-08-06 |
Sponsor Name:National Research, Development and Innovation Office | ||
Full Title: The prognostic value of Biomarkers and the Effect of Tolperisone in Acute low back pain and sciatic pain – BETA A Phase 3 investigator initiated study | ||
Medical condition: Acute low back pain with or withour radicular signs | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2012-005395-34 | Sponsor Protocol Number: CTC-cDDP | Start Date*: 2013-04-25 |
Sponsor Name:Erasmus MC | ||
Full Title: Prospective evaluation of the predictive value of a circulating tumor cell (CTC) sensitivity profile to Cisplatin chemotherapy in metastatic breast cancer patients | ||
Medical condition: Metastatic breast cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-012218-30 | Sponsor Protocol Number: ML22648 | Start Date*: 2009-10-06 |
Sponsor Name:Roche Farmacêutica Química, Lda. | ||
Full Title: A randomized, double-blind, placebo-controlled study to assess the efficacy of tocilizumab (TCZ) + non-biological DMARD in reducing synovitis as measured by magnetic resonance imaging (MRI) at 12 w... | ||
Medical condition: Men and women > 18 years of age with RA who are currently experiencing an inadequate clinical response to a stable dose of non-biologic DMARDs (at least 12 weeks) and with MRI documented synovitis ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: PT (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-002589-30 | Sponsor Protocol Number: CHUBX2015/17 | Start Date*: 2018-01-29 |
Sponsor Name:CHU DE BORDEAUX | ||
Full Title: Dynamic Contrast enhanced ultrasound for predict and assess rectal cancer response after neo-adjuvant chemoradiation – RECT | ||
Medical condition: Rectal Cancer | ||
Disease: | ||
Population Age: | Gender: | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-004159-19 | Sponsor Protocol Number: 2018-00938 | Start Date*: Information not available in EudraCT |
Sponsor Name:University Hospital Basel | ||
Full Title: Use of Copeptin Measurement after Arginine Infusion for the Diagnosis of Diabetes Insipidus - the CARGOx Study | ||
Medical condition: Polyuria-polydipsia syndrome (PPS) is divided into the three main entities central (complete or partial) diabetes insipidus (DI), nephrogenic DI and primary polydipsia (PP). | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Ongoing) NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2022-002585-33 | Sponsor Protocol Number: PETAL | Start Date*: 2023-01-19 | ||||||||||||||||
Sponsor Name:FONDAZIONE TOSCANA GABRIELE MONASTERIO | ||||||||||||||||||
Full Title: A multi-center phase 3 study of 18F-florbetaben positron emission tomography/computed tomography (PET-CT) | ||||||||||||||||||
Medical condition: cardiac amyloidosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005573-21 | Sponsor Protocol Number: GLIOMARK1 | Start Date*: 2016-04-26 | |||||||||||
Sponsor Name:pro-ACTINA S.A. | |||||||||||||
Full Title: Exploratory phase II study in patients after treatment of high grade brain tumors to assess the technical performance of Tc-99m tetrofosmin for differentiation of recurrence versus radiation necrosis | |||||||||||||
Medical condition: Patients with high grade brain tumors | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) HU (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-005064-15 | Sponsor Protocol Number: M14DPD | Start Date*: 2015-02-12 |
Sponsor Name:Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital (NKI-ALV) | ||
Full Title: Safety, feasibility and cost-effectiveness of genotype-directed individualized dosing of fluoropyrimidines | ||
Medical condition: Types of cancer for which capecitabine and 5-fluorouracil are authorized, this includes colorectal cancer, gastric cancer and locally advanced or metastatic breast cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
